The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Performance was driven by solid operating income growth in both U.S. and International segments, despite revenue headwinds from manufacturer list price reductions and customer losses.

Management attributed the U.S. revenue slowdown to faster-than-expected brand-to-biosimilar conversions at a large mail order customer and slower growth in the GLP-1 category.

Strategic positioning in specialty pharmaceuticals remains a core growth driver, supported by the full acquisition of OneOncology and its integration with existing MSO platforms.

Operational resilience was demonstrated by the global specialty logistics business, which achieved its second consecutive quarter of operating income growth following productivity initiatives.

Digital transformation efforts, including the launch of AI-supported tools, are being embedded across the enterprise to improve customer support quality and operational efficiency.

Portfolio optimization continues through the divestiture of non-core assets, such as U.S. hub consulting services, to focus resources on pharmaceutical-centric growth areas.

Full-year EPS guidance was raised to $17.65โ€“$17.90, primarily reflecting the accounting treatment of MWI as an asset held for sale, alongside strong operating income expectations and the resumption of share repurchases.

Revenue growth guidance was lowered to 4%โ€“6% to account for the accelerated pace of branded conversions and moderated GLP-1 volume assumptions.

Management expects the strongest operating income growth in the fourth quarter as the company laps the July 2025 loss of a major oncology customer.

The company plans to repurchase $1 billion in shares by the end of the calendar year, supported by an unchanged adjusted free cash flow target of approximately $3 billion.

Guidance assumes continued accretion from the OneOncology acquisition as shared capabilities in research and physician recruitment are scaled across the MSO platform.

Inclement weather in early Q2 resulted in a $10 million operating income headwind due to missed patient appointments at physician offices.

A $10 million year-over-year headwind was noted for COVID-19 vaccines, as the company lapped a $15 million contribution from the prior year period.

MWI Animal Health is now classified as an asset held for sale, which suspended depreciation expenses and contributed to higher operating income guidance for the 'Other' segment.

Manufacturer list price (WAC) reductions, influenced by the Inflation Reduction Act, created a $2 billion revenue headwind in the quarter, though management remains confident in recouping dollar profit.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that while brand-to-biosimilar conversions in the mail-order (Part D) channel create revenue pressure, they are low-margin and do not significantly impact operating profit.

In contrast, biosimilar growth in the physician-administered (Part B) space is viewed as incrementally beneficial to both practices and Cencora's margins.

Growth is expected to ramp due to the lapping of a lost oncology customer in July, increasing accretion from OneOncology, and easier expense comparisons in the fourth quarter.

Management noted that excluding specific customer losses and acquisitions, core U.S. growth is trending at approximately 7%, consistent with long-term targets.

Management expressed high confidence in maintaining absolute dollar profit despite lower drug prices by demonstrating the value of their highly automated distribution network and specialized services.

The company relies on commercial negotiations to ensure manufacturers recognize the efficiency and capital savings provided by the wholesale model.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.